Company research
Kodiak Sciences Inc.
CIK 1468748Updated Sep 27, 2026
SecurityKOD · NASDAQ · equity
Name history
Oligasis, LLC · through Jul 28, 2009
KOD price & chart
Loading TradingView…
NASDAQ:KOD on TradingView ↗About the company
Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study, with topline data expected in September 2026. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.
In the news
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock News provided by Kodiak Sciences Inc. Dec 16, 2025, 22:55 ET Share this article Share to X Share this article Share to X PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a precommercial ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 351,533,000Source | 335,578,000Source | 479,372,000Source | 666,628,000Source |
| Property, Plant and Equipment, NetUSD | 85,258,000Source | 102,222,000Source | 120,482,000Source | 56,384,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 209,862,000Source | 168,074,000Source | 285,507,000Source | 190,433,000Source |
| Assets, CurrentUSD | 214,816,000Source | 171,936,000Source | 289,309,000Source | 486,005,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,954,000Source | 3,862,000Source | 3,802,000Source | 7,072,000Source |
| Operating Lease, Right-of-Use AssetUSD | 36,606,000Source | 46,508,000Source | 54,541,000Source | 59,369,000Source |
| Other Assets, NoncurrentUSD | 8,669,000Source | 8,728,000Source | 8,716,000Source | 58,546,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 194,150,000Source | 185,290,000Source | 213,591,000Source | 230,461,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 5,000Source | 5,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,558,705,000Source | -1,328,738,000Source | -1,152,531,000Source | -892,040,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 0Source | -1,307,000Source |
| Stockholders' Equity Attributable to ParentUSD | 157,383,000Source | 150,288,000Source | 265,781,000Source | 436,167,000Source |
| Additional Paid in Capital, Common StockUSD | 1,716,082,000Source | 1,479,021,000Source | 1,418,307,000Source | 1,329,509,000Source |
| Liabilities and EquityUSD | 351,533,000Source | 335,578,000Source | 479,372,000Source | 666,628,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 45,533,000Source | 25,573,000Source | 41,729,000Source | 52,496,000Source |
| Operating Lease, Liability, CurrentUSD | 12,063,000Source | 10,628,000Source | 9,770,000Source | 9,926,000Source |
| Accounts Payable, CurrentUSD | 12,863,000Source | 3,915,000Source | 13,608,000Source | 9,130,000Source |
| Operating Lease, Liability, NoncurrentUSD | 47,117,000Source | 59,717,000Source | 71,862,000Source | 77,807,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 162,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 20,607,000Source | 11,030,000Source | 18,351,000Source | 33,440,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 58,863,000Source | 60,213,000Source | 88,556,000Source | 106,033,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 8,070,000Source | -9,693,000Source | 5,597,000Source | 1,660,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -136,008,000Source | -117,319,000Source | -154,183,000Source | -206,459,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -506,000Source | -755,000Source | 249,226,000Source | -336,513,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 506,000Source | 375,000Source | 41,350,000Source | 37,021,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 178,302,000Source | 501,000Source | 31,000Source | 1,895,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 13,000Source | 18,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 58,863,000Source | 60,213,000Source | 88,556,000Source | 106,033,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | 0Source |
| DepreciationUSD | 18,328,000Source | 18,710,000Source | 18,298,000Source | 3,796,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -1,000,000Source | 300,000Source | 100,000Source | -300,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | -355,000Source | 0Source | 616,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | 0Source | -2,000Source | — |
| General and Administrative ExpenseUSD | 52,015,000Source | 60,754,000Source | 71,023,000Source | 73,788,000Source |
| Income Tax Expense (Benefit)USD | 52,000Source | 20,000Source | 33,000Source | 33,000Source |
| Investment Income, InterestUSD | 4,517,000Source | 11,148,000Source | 16,733,000Source | 7,071,000Source |
| Net Income (Loss) Attributable to ParentUSD | -229,967,000Source | -176,207,000Source | -260,491,000Source | -333,823,000Source |
| Operating ExpensesUSD | 234,388,000Source | 186,849,000Source | 277,321,000Source | 341,379,000Source |
| Other Nonoperating Income (Expense)USD | -96,000Source | -506,000Source | 110,000Source | 503,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 5,162,000Source | 394,000Source | 60,000Source | 1,770,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -234,388,000Source | -186,849,000Source | -277,321,000Source | -341,379,000Source |
| Other Nonoperating Income (Expense)USD | -96,000Source | -506,000Source | 110,000Source | 503,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -229,915,000Source | -176,187,000Source | 260,432,000Source | 333,790,000Source |
| Income Tax Expense (Benefit)USD | 52,000Source | 20,000Source | 33,000Source | 33,000Source |
| Net Income (Loss) Attributable to ParentUSD | -229,967,000Source | -176,207,000Source | -260,491,000Source | -333,823,000Source |
| Earnings Per Share, BasicUSD per share | -4.32Source | -3.35Source | -4.97Source | -6.39Source |
| Earnings Per Share, DilutedUSD per share | -4.32Source | -3.35Source | -4.97Source | -6.39Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 53,208,311Source | 52,583,148Source | 52,414,256Source | 52,249,620Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 53,208,311Source | 52,583,148Source | 52,414,256Source | 52,249,620Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 20,000Source | 33,000Source | 33,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -1,000,000Source | 300,000Source | 100,000Source | -300,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | -355,000Source | 0Source | 616,000Source |
| General and Administrative ExpenseUSD | 52,015,000Source | 60,754,000Source | 71,023,000Source | 73,788,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -154,535,000Source | -118,783,000Source | -143,256,000Source | -163,240,000Source |
| Interest ExpenseUSD | 0Source | 0Source | 13,000Source | 18,000Source |
| Investment Income, InterestUSD | 4,517,000Source | 11,148,000Source | 16,733,000Source | 7,071,000Source |
| Operating ExpensesUSD | 234,388,000Source | 186,849,000Source | 277,321,000Source | 341,379,000Source |
| Research and Development ExpenseUSD | 182,373,000Source | 126,095,000Source | 206,298,000Source | 267,591,000Source |
Filing attachments
kod-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said V…
Read attachment ↗kod-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Palo Alto, Calif., May 7, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said …
Read attachment ↗kod-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results PALO ALTO, Calif., March 31, 2026 - Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advanc…
Read attachment ↗d283186dex991.htm · 8-K · 2026-03-27
EX-99.1 2 d283186dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda ™ (tarcocimab tedromer) Over Sham Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severit…
Read attachment ↗kod-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results Palo Alto, Calif., November 13, 2025 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. “Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution and growing external enthusias…
Read attachment ↗kod-ex99_1.htm · 8-K · 2025-08-13
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results Palo Alto, Calif., August 13, 2025 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. “Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets - tarcocimab, KSI…
Read attachment ↗